29267263|t|CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.
29267263|a|Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a rapidly progressive fatal neurologic disease. Currently, there is no cure for ALS and the available treatments only extend life by an average of a few months. The majority of ALS patients die within 2-5 years of diagnosis, though survival time varies depending on disease progression (1,2). For approximately 10% of patients, ALS is familial, meaning it and has a genetic component; the remaining 90% have sporadic ALS, where etiology is unknown, but might be linked to environmental factors such as chemical exposures (e.g., heavy metals, pesticides) and occupational history (3).
29267263	27	56	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
29267263	58	61	ALS	Disease	MESH:D000690
29267263	115	144	Amyotrophic lateral sclerosis	Disease	MESH:D000690
29267263	146	149	ALS	Disease	MESH:D000690
29267263	170	190	Lou Gehrig's disease	Disease	MESH:D000690
29267263	223	241	neurologic disease	Disease	MESH:D020271
29267263	275	278	ALS	Disease	MESH:D000690
29267263	372	375	ALS	Disease	MESH:D000690
29267263	376	384	patients	Species	9606
29267263	513	521	patients	Species	9606
29267263	523	526	ALS	Disease	MESH:D000690
29267263	612	615	ALS	Disease	MESH:D000690
29267263	723	735	heavy metals	Chemical	MESH:D019216
29267263	Positive_Correlation	MESH:D019216	MESH:D000690

